Patents Assigned to GW Pharma Limited
  • Patent number: 10653641
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 19, 2020
    Assignee: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Publication number: 20200138771
    Abstract: The invention relates to the use of a combination of cannabinoids, particularly tetrahydrocannabinol (THC) and cannabidiol (CBD), in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multifonne (GBM).
    Type: Application
    Filed: June 7, 2019
    Publication date: May 7, 2020
    Applicant: GW Pharma Limited
    Inventors: Guillermo VELASCO DIEZ, Manuel GUZMAN PASTOR, Mar LORENTE, Sofia TORRES, Fatima RODRIGUEZ
  • Publication number: 20200102131
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: December 3, 2019
    Publication date: April 2, 2020
    Applicant: GW Pharma Limited
    Inventor: BRIAN ANTHONY WHITTLE
  • Patent number: 10538373
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: January 21, 2020
    Assignee: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Publication number: 20190322427
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: January 11, 2019
    Publication date: October 24, 2019
    Applicant: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Publication number: 20190270563
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Application
    Filed: May 21, 2019
    Publication date: September 5, 2019
    Applicant: GW Pharma Limited
    Inventor: BRIAN ANTHONY WHITTLE
  • Publication number: 20190255011
    Abstract: The invention relates to the use of a cannabis plant extract or a cannabinoid as a pharmaceutically active agent in the inhibition of tumour cell migration.
    Type: Application
    Filed: September 26, 2018
    Publication date: August 22, 2019
    Applicant: GW Pharma Limited
    Inventors: Brian Anthony WHITTLE, Daniela PAROLARO
  • Publication number: 20190224140
    Abstract: The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably, the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.
    Type: Application
    Filed: September 26, 2018
    Publication date: July 25, 2019
    Applicant: GW Pharma Limited
    Inventors: Geoffrey Guy, Barbara Costa
  • Patent number: 10258580
    Abstract: The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: April 16, 2019
    Assignee: GW Pharma Limited
    Inventors: Teresa Iuvone, Vincenzo Di Marzo, Geoffrey Guy, Stephen Wright, Colin Stott
  • Publication number: 20190099398
    Abstract: The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer. Preferably the phytocannabinoids used are either tetrahydrocannabinol (THC) and/or cannabidiol (CBD). Preferably the type of cancer to be treated is glioma.
    Type: Application
    Filed: May 2, 2018
    Publication date: April 4, 2019
    Applicant: GW Pharma Limited
    Inventors: Wai LIU, Katherine SCOTT, Angus DALGLEISH, Marnie Duncan, Colin Stott
  • Publication number: 20190099492
    Abstract: The invention relates to the use of one or more cannabinoids, particularly THC and/or CBD in combination with a non-cannabinoid chemotherapeutic agent in the manufacture of a medicament for use in the treatment of cancer. In particular the cancer to be treated is a brain tumour, more particularly a glioma, more particularly still a glioblastoma multiforme (GBM). The non-cannabinoid chemotherapeutic agent may be a selective estrogen receptor modulator or an alkylating agent.
    Type: Application
    Filed: May 1, 2018
    Publication date: April 4, 2019
    Applicant: GW Pharma Limited
    Inventors: Guillermo VELASCO DIEZ, Manuel GUZMAN PASTOR, Mar LORENTE, Sofia TORRES
  • Patent number: 10195159
    Abstract: Processes for preparing extracts of natural products such as plant material, and for preparing purified extracts from crude extracts of natural products, by extraction with hot gas. Apparatus suitable for use in preparing extracts of natural products are also described.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: February 5, 2019
    Assignee: GW Pharma Limited
    Inventors: Brian Anthony Whittle, Geoffrey Guy, David Victor Downs, David W. Pate
  • Patent number: 10179683
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: April 14, 2015
    Date of Patent: January 15, 2019
    Assignee: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Publication number: 20180344660
    Abstract: This invention relates to the use of CBD to treat mental disorders.
    Type: Application
    Filed: September 8, 2016
    Publication date: December 6, 2018
    Applicant: GW Pharma Limited
    Inventors: Philip Robson, Geoffrey Guy, Stephen Wright, Emma Cheetham, Dominic Schiller
  • Patent number: 10137095
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 27, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 10111840
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: October 30, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Patent number: 10092525
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 9, 2018
    Assignee: GW Pharma Limited
    Inventors: Geoffrey Guy, Stephen Wright, Alice Mead, Orrin Devinsky
  • Publication number: 20180263952
    Abstract: The present invention relates to the use of one or more cannabinoids in the treatment of an inflammatory skin disease. Preferably the one or more cannabinoids are taken from the group consisting of: cannabidiol (CBD), cannabidiolic acid (CBDA), cannabidivarin (CBDV), cannabigerol (CBG), cannabigervarin (CBGV) and tetrahydrocannabivarin (THCV). The inflammatory skin disease may be caused by one or more of the following: microbial infection-induced dermatitis; solar dermatitis; atopic dermatitis; and allergic contact dermatitis.
    Type: Application
    Filed: September 29, 2016
    Publication date: September 20, 2018
    Applicant: GW Pharma Limited
    Inventors: Tamás Bíró, Colin Stott, Vincenzo Di Marzo
  • Patent number: 10004684
    Abstract: The invention relates to pharmaceutical formulations for use in the administration of lipophilic medicaments via mucosal surfaces. In particular the invention provides pharmaceutical formulations for use in administration of a lipophilic medicament via a mucosal surface which upon hydration form an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament. The invention further provides pharmaceutical formulations which contain, as active ingredients, specific combinations of cannabinoids in pre-defined ratios.
    Type: Grant
    Filed: February 14, 2002
    Date of Patent: June 26, 2018
    Assignee: GW Pharma Limited
    Inventors: Brian Whittle, Geoffrey Guy
  • Patent number: 9962341
    Abstract: The present invention relates to an active pharmaceutical ingredient (API) which comprises or consists essentially of cannabidiol (CBD) and one other cannabinoid selected from cannabigerol (CBG), cannabigerolic acid (CBGA), cannabidiolic acid (CBDA), and tetrahydrocannabivarin (THCV) for use as a medicament, and more particularly, for use in the treatment of cancer. These combinations have shown themselves to be synergistic in treating one or more of: breast cancer; liver cancer; lung cancer; pancreatic cancer; melanoma; ovarian cancer; gastric cancer; renal cancer or bladder cancer. Two particularly favored API combinations are: cannabidiol (CBD) and cannabigerol (CBG); and cannabidiolic (CBD) and tetrahydrocannabivarin (THCV).
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: May 8, 2018
    Assignee: GW Pharma Limited
    Inventors: Colin Stott, Marnie Duncan, Thomas Hill